ProShare Advisors
BIOL

ProShare Advisors’s Biolase, Inc. BIOL Stock Holding History

ProShare Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3
Closed -$84K – 2640
2014
Q1 		$84K Buy
+3
New +$105K ﹤0.01% 2704
2013
Q4 		– Sell
-2
Closed -$38K – 1935
2013
Q3 		$38K Buy
+2
New +$64.4K ﹤0.01% 2516

Other funds holding BIOL

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TA
Teton Advisors Rye, New York $142M AUM 42.07% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

ProShare Advisors's BIOL Position: Q2 2014 in Review

ProShare Advisors sold out of Biolase, Inc. (BIOL) in Q2 2014, closing a stake of 3 shares — an estimated $84K sold.

ProShare Advisors first reported a position in BIOL in Q3 2013 and held it in 2 quarters. The position peaked at $84K in Q1 2014. 34 funds tracked by Wall St. Rank hold BIOL as of Q2 2014.

  • ProShare Advisors reported no remaining Biolase, Inc. position as of Q2 2014 after selling out during the quarter.
  • ProShare Advisors sold 3 Biolase, Inc. shares in Q2 2014, an estimated $84K.
  • ProShare Advisors first reported a position in Biolase, Inc. in Q3 2013 and held it in 2 quarters.
  • ProShare Advisors's Biolase, Inc. position peaked at $84K in Q1 2014.
  • 34 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2014.

Based on ProShare Advisors's 13F filing for Q2 2014, filed 8 Aug 2014.